Dr Josep Ribera speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses the NEUF study which looks at the treatment of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia with blinatumomab in a real-world setting.
He outlines the trial design, results and toxicity profile.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.